ArticleInternational ophthalmology2021
Ocular surface squamous neoplasia at a tertiary eye facility, Southwestern Nigeria: a 10-year review.
Article in International ophthalmology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.
- Formulation of treatment protocol for ocular surface squamous neoplasia.International ophthalmology · 2026Pooled it
- TFOS lifestyle: Impact of societal challenges on the ocular surface.The ocular surface · 2023Pooled it
- Effective Management of Recurrent Conjunctival Intraepithelial Neoplasia Using Topical Mitomycin C 0.02.Cureus · 2026Article
- Clinical profile and outcomes of ocular surface squamous neoplasia at the Philippine General Hospital: a retrospective study.International journal of ophthalmology · 2025Article
- Ocular Surface Squamous Neoplasia in Renal Transplant Patients.Beyoglu eye journal · 2024Article
- Clinicopathological characteristics of ocular surface squamous neoplasia: a 10-year review form a referral tertiary centre in Nigeria.International ophthalmology · 2022Article
- Ocular surface squamous neoplasia in India: a study of 438 patients.International ophthalmology · 2022Article
- Corneal ocular surface squamous neoplasia: Case series and review of literature.Oman journal of ophthalmologyArticle
- Pigmented versus nonpigmented ocular surface squamous neoplasia: A comparative study of 424 tumors.Taiwan journal of ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOcular surface squamous neoplasia (OSSN) is a low-grade malignancy arising from the squamous epithelium of the ocular surface
aimTo describe the clinical presentation, histological diagnoses, treatment, and outcome of treatment in patients with OSSN managed at a tertiary health facility.
methodsMedical records of all patients with OSSN managed using a standardized treatment protocol over a 10-year period were reviewed.
resultsEighty-six patients comprising 44 (51.2%) males and mean age of 48.2 ± 15.8 years were studied. The most common presentation was a fleshy growth in the eye in all patients, and 43 (50.0%) patients tested positive to human immunodeficiency virus. The right eye was affected in 44 (51.2%) patients with no bilateral tumors, and the medial limbus was involved in 28 (32.6%) patients. Morphologically, 40 (46.5%) patients had gelatinous growth, 24 (27.9%) patients were in T
conclusionOSSN occurs more commonly in younger age group in our studied population and is strongly associated with HIV seropositivity. Intraoperative cryotherapy in patients with carcinoma in situ and intraoperative cryotherapy with adjuvant topical mitomycin C in those with invasive SCC that is limited to the ocular surface are associated with low tumor recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.